Member Info for roses

Valju - surely that should be "I'd buy that for 1p"

They have been saying that for years. If there was anything of substance actually going on then it would have leaked in some form by now to those in the know and been reflected in the shareprice.

This is Aim after all !

It's a nice thought but illegal.

The company has to release any share price impacting info as soon as they are aware of it.

gaf1 - one year, really ? it's been in freefall since it listed around 2008 at the equivalent of £54.23
(today around £0.01p)

"no filters will be removed, until conclusion of Val"

Be careful what you wish for, it may be sooner than you think ?

My deepest sympathy wolfstreet, I'm sure your money will miss you very much.

hardtohandle - I started to question that as soon as they announced that they were doing their trials in some outpost on the Russian border.

meanwhile most shareholders haven't got a pot to piss in !

Noise - would you care to explain ?

Technicalities in clinical trials are very important !

Dracula -I'm sorry but you are wrong. val401 was trialed as a cure for cancer and failed to meet it's primary and secondary endpoints in it's clinical trial and the trial is now aiming at a beefed up pain killer for palliative care.

Valju - the company can't just magic up an RNS every time you get bored.

It is illegal for them not to release price sensitive information as soon as they are aware about it.

Ergo there is no news at the moment.

Investment case

Scancell has two promising technology platforms for therapeutic vaccines that have the potential to treat many cancers, either as monotherapy or in combination with checkpoint inhibitors. Many therapeutic vaccines have failed to fulfil their potential; but the strength of the cellular immune responses stimulated by both ImmunoBody and Moditope, and the resultant anti-tumour activity observed to date in clinical and preclinical studies augers well. The financial issues that have hindered development of these products are being overcome, so a Phase II study with ImmunoBody SCIB1 and a Phase I/II with the first Moditope product are expected to start during CY19.

We value the company, using a risk-adjusted DCF model, at £82.0m, or 21.1p a share.

Correct this company has been paid by Valirx in shares and cash to produce a positive sounding report

The spelling "commercial right(s)" with an 's' can be and is used for a single product

Valju - the "agreed commercial rights" the company alludes to is the mystical Mystic deal which gave us no money and is giving us no income

Lol, 'the evaporation of shares' is that another name for share consolidation

Tire and confused - You also missed the 30-1 consolidation a few years before that

Which makes the initial offering price a staggering £54 in todays money

No, my position is that no one knows except the BOD, and they refuse to tell us.

Adam - headline data is useless without context and facts and figures.

401 headline data stated that it failed to meet its primary and secondary endpoints.

The thing is Adam, we don't actually know if any progress has been made at all.

For some reason, the BOD refuse to release the trial results in full and until they do then we must assume something isn't quite right.